Pappas Ventures and our portfolio companies often make headlines. Whether it’s about incredible new discoveries that improve patient care or notable success stories, there’s always something interesting happening.


News and Events

October 17, 2016

Envisia Therapeutics Releases ENV515 (travoprost XR) Phase 2 Data Showing Nine-Month Duration Of Action After A Single Dose In Patients With Glaucoma

learn more »

September 28, 2016

Athersys Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Study of MultiStem® Treatment for Ischemic Stroke

learn more »

September 6, 2016

CoLucid Pharmaceuticals Announces Achievement of Both Primary and Key Secondary Endpoints in the SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine

learn more »

August 18, 2016

Rotation Medical Secures $12 Million in Series B Extension Financing

learn more »

July 18, 2016

IlluminOss Medical Completes Enrollment for U.S. Clinical Trial Using Groundbreaking Photodynamic Bone Stabilization System

learn more »

July 6, 2016

Syndax Expands Pipeline With Exclusive Worldwide License Agreement for UCB’s Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program

learn more »

June 10, 2016

Merck to Acquire Afferent Pharmaceuticals

learn more »

June 7, 2016

CoLucid Pharmaceuticals Announces Last Patient Randomized in SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine

learn more »

May 19, 2016

CoLucid Pharmaceuticals Announces Initiation of Second Phase 3 Pivotal Trial of Lasmiditan in Migraine

learn more »

May 4, 2016

Envisia Therapeutics Announces Positive Three-Month Interim Results of Low Dose ENV515 in Patients with Glaucoma

learn more »

April 26, 2016

Afferent Pharmaceuticals Announces Presentations of Chronic Cough Clinical Data and Hypertension Research for the Upcoming American Thoracic Society (ATS) 2016 International Conference

learn more »

March 23, 2016

Envisia Therapeutics Secures $16.5 Million In Additional Series A Financing

learn more »

March 2, 2016

Syndax Announces Pricing of Initial Public Offering

learn more »

March 1, 2016

CoLucid Pharmaceuticals Announces Special Protocol Agreement for SPARTAN

learn more »

February 29, 2016

Thrasos Announces Promising Results for Phase 2 THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI)

learn more »

February 23, 2016

CoLucid Pharmaceuticals Announces Confirmatory Support for Non-vasoconstrictive Mechanism of Action for Lasmiditan

learn more »

February 17, 2016

One-Year Results From Phase 2 Stroke Study of MultiStem® Cell Therapy Demonstrate a Significantly Higher Rate of Complete or Nearly Full Recovery

learn more »

January 13, 2016

Envisia Therapeutics Announces First Patient Dosed in Second Cohort of Novel Phase 2 Program Evaluating ENV515 in Patients with Glaucoma

learn more »

January 8, 2016

Healios and Athersys Enter Into Regenerative Medicine Partnership for Treatment of Stroke Using MultiStem(R) Therapy

learn more »

January 5, 2016

Afferent Pharmaceuticals named one of “The Hottest Startups of 2015” by Forbes

learn more »

January 4, 2016

Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer

learn more »

December 8, 2015

Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phase 1 Clinical Trial

learn more »

December 1, 2015

Syndax Announces Initiation Of Entinostat Clinical Program In Japan By Partner Kyowa Hakko Kirin

learn more »

November 30, 2015

CoLucid Pharmaceuticals Provides SAMURAI Enrollment Update

learn more »

November 19, 2015

Afferent Pharmaceuticals Expands Executive Leadership Team With Appointments of Prabha N. Ibrahim, PhD, as Chief Technology Officer and Michelle Carpenter, JD, RAC, as Vice President, Regulatory Affairs and Project Management

learn more »

November 11, 2015

Afferent Pharmaceuticals Announces Phase 2 Clinical Trial with AF-219 in Cough in Idiopathic Pulmonary Fibrosis (IPF) Patients

learn more »

November 10, 2015

Thrasos Strengthens Composition of Matter Coverage on THR-184 with Japanese Patent Decision

learn more »

October 27, 2015

CoLucid Pharmaceuticals Announces Election of Mark Corrigan, M.D., to Board of Directors

learn more »

October 9, 2015

ENVISIA THERAPEUTICS’ LEAD PRODUCT CANDIDATE, ENV515 (travoprost XR), ACHIEVES PRIMARY EFFICACY ENDPOINT IN PHASE 2A GLAUCOMA CLINICAL TRIAL

learn more »

October 9, 2015

Chimerix Presents Preliminary Data on Brincidofovir in Liver Transplant Recipients With Adenovirus Infections at IDWeek in San Diego

learn more »

October 9, 2015

CoLucid Pharmaceuticals Announces Initiation of Phase 3 Long-Term, Open-Label Trial of Lasmiditan in Migraine.

learn more »

October 9, 2015

Medtronic TYRX(TM) Neuro Absorbable Antibacterial Envelope now Available for Use with Implantable Neurostimulators

learn more »

October 8, 2015

Wake Forest Baptist Medical Center Creates $15 Million Program to Develop Life Science Technologies

learn more »

October 2, 2015

Anthera Announces Initiation of the SOLUTION Clinical Study of Oral Sollpura(R) (liprotamase) Unit-Matched Therapy of Non-Porcine Origin in People With Cystic Fibrosis

learn more »

September 30, 2015

Liquidia Technologies and GlaxoSmithKline Advance Existing Collaboration; GlaxoSmithKline Exercises Option for Inhaled Therapeutics

learn more »

September 28, 2015

Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial

learn more »

September 17, 2015

CardioDx Expands Patient Access to the Corus(R) CAD Test Through National Agreement With Quest Diagnostics

learn more »

September 2, 2015

TESARO Announces U.S. FDA Approval of VARUBI™ (rolapitant) for Nausea and Vomiting Associated with Cancer Chemotherapy

learn more »

September 2, 2015

Chimerix and BARDA Announce Continued Partnership in the Development of Brincidofovir for Smallpox

learn more »

August 26, 2015

SYNDAX ENTERS CLINICAL TRIAL COLLABORATION IN CANCER IMMUNOTHERAPY COMBINING ENTINOSTAT AND ATEZOLIZUMAB

learn more »

August 24, 2015

SYNDAX RAISES $80 MILLION IN SERIES C FINANCING

learn more »

August 18, 2015

Rotation Medical Featured in Local News Story

learn more »

July 21, 2015

IlluminOss Medical Appoints Clive Ridgwell as Vice President of Sales

learn more »

July 14, 2015

Liquidia Technologies Names Robert A. Lippe Chief Operations Officer

learn more »

July 8, 2015

Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury

learn more »

July 8, 2015

Afferent Pharmaceuticals Raises $55 Million in Oversubscribed Crossover Financing

learn more »

June 15, 2015

Milestone Pharmaceuticals Closes US$17 Million Series B Financing to Complete Phase 2 Clinical Studies for MSP-2017

learn more »

May 6, 2015

CoLucid Pharmaceuticals Announces Pricing of Initial Public Offering

learn more »

May 4, 2015

Envisia Therapeutics to Present at ARVO 2015 Annual Meeting

learn more »

April 29, 2015

IlluminOss Medical Appoints Amy Orlick Berman as Vice President of Clinical Affairs

learn more »

April 28, 2015

CoLucid Pharmaceuticals Announces Initiation of First Phase 3 Pivotal Trial of Lasmiditan in Migraine

learn more »

April 14, 2015

Envisia Therapeutics Names Dr. Rhett Schiffman Chief Medical Officer

learn more »

March 31, 2015

Thrasos Secures $21 Million to Complete Phase 2 Study of THR-184 in the Prevention of Acute Kidney Injury and Expand the Company’s Renal Portfolio

learn more »

March 31, 2015

Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma

learn more »

March 24, 2015

IlluminOss Medical Announces the Enrollment of First Patient in Proximal Humerus Fracture Repair Trial at Albert Schweitzer Hospital

learn more »

March 19, 2015

A drug that could raise IQ – Balance Therapeutics raises $18M, conducting Down Syndrome trials

learn more »

March 19, 2015

Anthera Announces $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Development of Sollpura – a Novel Enzyme Therapy

learn more »

March 16, 2015

Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for IgA Nephropathy

learn more »

March 3, 2015

IlluminOss Medical Announces the Enrollment of First Patient in EU Humerus Fracture Repair Trial

learn more »

March 2, 2015

Athersys and Chugai Enter License Agreement and Collaboration to Develop MultiStem(R) Cell Therapy for Ischemic Stroke in Japan

learn more »

February 8, 2015

Triangle Global Health Consortium Recognizes Chimerix with 2015 Corporate Impact Award

learn more »

January 27, 2015

Envisia Therapeutics Initiates Phase 2a Clinical Trial for ENV515 in Patients with Glaucoma

learn more »

January 22, 2015

Athersys and Cell Therapy Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition

learn more »

January 13, 2015

CoLucid Pharmaceuticals, Inc., Raises $37.1 Million in Series C Preferred Stock Offering

learn more »

January 12, 2015

Chimerix Receives Notice of Allowance for Brincidofovir Composition of Matter Patent Extending Exclusivity to 2034

learn more »

January 12, 2015

Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND

learn more »

January 7, 2015

Ultragenyx Announces License of Intellectual Property Related to the Treatment of Huntington’s Disease With Triheptanoin

learn more »

January 7, 2015

Mirati Therapeutics Doses First Patient in Phase 2 Study of Mocetinostat in Bladder Cancer Patients with Genetic Alterations of CREBBP and EP300

learn more »

January 7, 2015

Kyowa Hakko Kirin and Syndax Announce an Exclusive License Agreement to Develop and Commercialize Entinostat in Japan and Korea

learn more »

January 6, 2015

Mirati Therapeutics Doses First Patient in Investigator-Sponsored Phase 2 Study of Mocetinostat in Non-Hodgkin’s Lymphoma

learn more »

January 6, 2015

Ultragenyx Initiates New Development Program Studying KRN23 for the Treatment of Tumor-Induced Osteomalacia

learn more »

January 5, 2015

New Clinical Trial Will Evaluate Antibacterial Envelope in Cardiac Implantable Electronic Device Patients at Risk for Major Infections

learn more »

December 29, 2014

Athersys Finishes Enrollment of Phase 2 Study of MultiStem(R) Cell Therapy for Ischemic Stroke Top-Line Data Readout Expected Around the End of the First Quarter, 2015

learn more »

December 23, 2014

Mirati Therapeutics Doses First Patient in Expansion Cohorts of Phase 1b Trial of MGCD265 in Genetically Selected Patients

learn more »

December 18, 2014

CardioDx Raises $35 Million in Equity Financing

learn more »

December 18, 2014

Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157

learn more »

December 15, 2014

Anthera Pharmaceuticals Licenses Japan Rights for Blisibimod to Zenyaku Kogyo Co., Ltd.

learn more »

December 15, 2014

Ultragenyx Announces Initiation of Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7

learn more »

December 10, 2014

IlluminOss Medical Caps off Flagship Year with Addition of New Patents to Bone Fixation Portfolio

learn more »

November 25, 2014

Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough is Published in The Lancet

learn more »

November 24, 2014

Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients

learn more »

November 18, 2014

IlluminOss Medical Announces Conditional FDA Approval for Clinical Trials of Groundbreaking Photodynamic Bone Stabilization System in the U.S.

learn more »

November 13, 2014

Chimerix’s Brincidofovir Selected for Use in Ebola Clinical Trial in West Africa by International Consortium

learn more »

November 8, 2014

Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)

learn more »

November 6, 2014

Michael Grey Joins Mirati Therapeutics Board of Directors

learn more »

October 30, 2014

Ultragenyx Granted EU Orphan Drug Designation for KRN23 for the Treatment of X-Linked Hypophosphatemia

learn more »

October 28, 2014

Chimerix hammers out an emergency PhII Ebola study for antiviral

learn more »

October 27, 2014

Ultragenyx Granted Orphan Drug Designation for Triheptanoin for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome

learn more »

October 20, 2014

CardioDx Announces Results of Study Demonstrating the Benefits of the Corus CAD Gene Expression Test Use in an African American Patient Population

learn more »

September 25, 2014

LabCorp Announces Agreement to Acquire LipoScience

learn more »

September 22, 2014

Medtronic Announces CE Mark and European Launch of TYRX(TM) Absorbable Antibacterial Envelope

learn more »

September 16, 2014

Thrasos Announces Successful Formal Interim Analysis and Clinical Update

learn more »

September 15, 2014

Rotation Medical Initiates Post-Market Clinical Study Of Rotator Cuff Repair System With Bioinductive Implant

learn more »

September 15, 2014

Ultragenyx Announces Positive Results From a Long-Term Phase 1/2 Study of KRN23 in Adult Patients With X-Linked Hypophosphatemia

learn more »

September 10, 2014

Pappas, Chiesi Venture Fund Joins Ranks of Pharma & VC Partnerships

learn more »

September 8, 2014

TESARO Announces Submission of Rolapitant New Drug Application (NDA) to U.S. Food and Drug Administration

learn more »

September 2, 2014

Chiesi Launches Venture Capital Fund via Strategic Collaboration with A. M. Pappas & Associates

learn more »

August 11, 2014

Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma

learn more »

August 5, 2014

Ultragenyx Announces License of Intellectual Property for the Treatment of Epilepsy and Other Seizure-Related Disorders With Triheptanoin

learn more »

July 31, 2014

New Data on Chimerix’s Brincidofovir Supports Safety and Antiviral Activity Against Multiple Life-Threatening DNA Viruses in Organ Transplant Recipients

learn more »

July 30, 2014

MedStar Union Memorial Hospital is First Hospital in Country to Offer Rotation Medical Rotator Cuff System for Minimally Invasive Rotator Cuff Procedures

learn more »

July 14, 2014

Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company

learn more »

July 7, 2014

CardioDx Announces Aetna and Coventry Health Coverage for Corus® CAD Gene Expression Test

learn more »

July 1, 2014

Ultragenyx Announces Initiation of a Phase 2 Study of KRN23 for Pediatric X-Linked Hypophosphatemia in the US and EU

learn more »

July 1, 2014

Rotation Medical Completes $27.2 Million Series B Financing

learn more »

June 24, 2014

Venture Partner Mike Grey named EY Entrepreneur Of The Year San Diego

learn more »

June 24, 2014

Ultragenyx Announces Results from Phase 1/2 Study of KRN23 in X-linked Hypophosphatemia in Adults

learn more »

June 17, 2014

Mirati Therapeutics Receives Orphan Drug Designation from U.S. Food & Drug Administration for Mocetinostat in Myelodysplastic Syndrome

learn more »

June 3, 2014

Thrasos Presents Preclinical Data Demonstrating THR-184 Prevents Loss of Kidney Function Following Acute Ischemic Injury

learn more »

May 14, 2014

Plexxikon Announces Promising Preliminary PLX3397 Phase 1 Extension Data in Patients with Pigmented Villonodular Synovitis (PVNS)

learn more »

May 12, 2014

Shire adds to rare disease portfolio with acquisition of Lumena Pharmaceuticals, bringing late stage compounds for rare GI/hepatic conditions

learn more »

May 12, 2014

TESARO Announces Successful Achievement of Primary and All Secondary Endpoints in Third and Final Phase 3 Trial of Rolapitant

learn more »

May 9, 2014

Lumena Pharmaceuticals Now Dosing Patients in the INDIGO Phase 2 Clinical Trial of LUM001 in Pediatric Patients with Progressive Familial Intrahepatic Cholestasis

learn more »

May 6, 2014

CoLucid Pharmaceuticals, Inc., Announces Agreement from the FDA on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Lasmiditan in Migraine Including Patients with Risk Factors for Cardiovascular Disease

learn more »

May 5, 2014

New Study Results Further Reinforce that the Corus® CAD Test Helps Primary Care Clinicians Make Effective Referral Decisions for Patients with Suspected Obstructive Coronary Artery Disease

learn more »

April 30, 2014

Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting

learn more »

April 23, 2014

MUSC Foundation for Research Development welcomes Art Pappas to board

learn more »

April 17, 2014

IlluminOss receives new patents for bone stabilization system

learn more »

March 27, 2014

Ultragenyx Announces Preliminary Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7

learn more »

March 11, 2014

Lumena Pharmaceuticals Raises $45 Million in Series B Financing

learn more »

March 11, 2014

Ultragenyx Announces First Patient Enrolled in Phase 2 Study of Triheptanoin in Glucose Transporter Type-1 Deficiency Syndrome

learn more »

March 10, 2014

Study Finds the Corus® CAD Gene Expression Blood Test Influenced Primary Care Decision- Making in the Assessment of Patients with Suspected Obstructive Coronary Artery Disease

learn more »

February 24, 2014

Marina Biotech Announces $6 MM Convertible Preferred Stock Financing and Conversion to Common Stock of the Company’s Promissory Note

learn more »

February 12, 2014

Ultragenyx Announces Presentation of Data From a Single Patient Treated With Recombinant Human Beta-Glucuronidase at 10th Annual World Lysosomal Disease Network Symposium

learn more »

February 11, 2014

Ultragenyx Announces Initiation of Phase 2 Study for Patients with Long-Chain Fatty Acid Oxidation Disorders

learn more »

February 6, 2014

Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board of Directors

learn more »

February 6, 2014

IlluminOss Medical introduces bone stabilization system in Spain, Israel

learn more »

February 5, 2014

Ultragenyx Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option to Purchase Additional Shares

learn more »

January 30, 2014

Ultragenyx Announces Pricing of Initial Public Offering

learn more »

January 22, 2014

LipoScience Announces Appointment of Howard Doran as President and Chief Executive Officer

learn more »

January 8, 2014

Pappas Ventures Promotes Scott Weiner to Partner

learn more »

January 6, 2014

Medtronic Announces Acquisition of TYRX, INC., Developer of Solutions for Surgical Site Infections

learn more »

December 20, 2013

Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy

learn more »

December 17, 2013

Ultragenyx Investigational New Drug Application for Triheptanoin for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome is in Effect

learn more »

December 10, 2013

Pappas Ventures Names Franz B. Humer as Venture Partner and Senior Advisor

learn more »

December 4, 2013

FDA Clears TYRX Antibacterial Envelope for Use with Spinal Cord Neuromodulators

learn more »

November 18, 2013

Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases

learn more »

November 12, 2013

Envisia Therapeutics Debuts with $25 Million Series A Financing

learn more »

November 5, 2013

Inhibition of ASBT Improves Liver Function in an Animal Model of Cholestatic Liver Disease

learn more »

October 29, 2013

Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis

learn more »

October 22, 2013

CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan, a Novel Agent for Acute Migraine

learn more »

October 10, 2013

New Data Highlight Value of Corus® CAD in Reducing Unnecessary Cardiac Testing and Costs for Women with Symptoms Suggestive of Obstructive Coronary Artery Disease

learn more »

October 6, 2013

Ultragenyx Announces the Presentation of Data from a Single Dose Phase 1 Study, Conducted by Kyowa Hakko Kirin Co. Ltd. (KHK), of KRN23 in X-linked Hypophosphatemia (XLH) in Adults

learn more »

October 2, 2013

Chimerix Announces Publication of Positive Phase 2 Results of Brincidofovir (CMX001) in the New England Journal of Medicine

learn more »

September 26, 2013

Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 18th Annual World Muscle Society Congress

learn more »

September 26, 2013

Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases

learn more »

September 26, 2013

Lumena Pharmaceuticals Launches Global Clinical Program to Evaluate Safety and Efficacy of LUM001 in Children with Alagille Syndrome

learn more »

September 24, 2013

Ultragenyx selected as 2013 Fierce 15 Company

learn more »

September 16, 2013

Ultragenyx Announces Positive Data from Retrospective Study of UX007 Triheptanoin in Patients with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

learn more »

September 11, 2013

Chimerix Presents Brincidofovir (CMX001) Adenovirus Phase 2 Results

learn more »

September 9, 2013

Chimerix Initiates Phase 3 SUPPRESS Trial of Brincidofovir (CMX001) for Prevention of CMV in HCT Recipients

learn more »

September 4, 2013

LipoScience Announces New Data Supporting High-Density Lipoprotein Particle (HDL-P) Number As Marker Of Cardiovascular Risk

learn more »

September 3, 2013

Ultragenyx Announces Collaboration with Kyowa Hakko Kirin to Develop and Commercialize Phase 2-stage KRN23 for X-linked Hypophosphatemia

learn more »

August 27, 2013

Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers

learn more »

August 14, 2013

Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus Study and Late-Breaker Presentation at ICAAC

learn more »

August 14, 2013

Ultragenyx Receives Approval of Clinical Trial Application (CTA) for a Phase 1/2 Trial TestingUX003 in Mucopolysaccharidosis Type 7 (MPS 7)

learn more »

August 12, 2013

TYRX Announces First U.S. Implantation of AIGISRx® R Fully Bioresorbable Antibacterial Envelope

learn more »

August 5, 2013

Ultragenyx Initiates New Development Program Studying Triheptanoin (UX007) for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)

learn more »

July 31, 2013

LipoScience Research Sheds Light On Novel Markers Via Nuclear Magnetic Resonance (NMR) Spectroscopy

learn more »

July 23, 2013

TESARO Initiates Phase 3 Trial of Niraparib for Treatment of Patients with Ovarian Cancer

learn more »

July 23, 2013

TYRX Receives FDA Clearance for AIGISRx® Neuro Antibacterial Envelope

learn more »

July 23, 2013

Stem cell therapy for transplants developed by Athersys Inc. may end need for long-term immunosuppressive drugs

learn more »

July 15, 2013

Chimerix CEO: Public market is critical to financing biotech R&D

learn more »

July 11, 2013

Ultragenyx Gains Worldwide Rights for Triheptanoin (UX007)

learn more »

July 9, 2013

TYRX Receives FDA Clearance for Fully Resorbable AIGISRx® R Antibacterial Envelope

learn more »

July 3, 2013

Ultragenyx Announces a Positive Signal in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy

learn more »

June 28, 2013

Mirati Therapeutics and MethylGene Announce Completion of Plan of Arrangement

learn more »

June 28, 2013

TESARO Announces Presentation of Rolapitant Pharmacokinetic (PK) Data at the MASCC/ISOO International Symposium

learn more »

June 26, 2013

Zero Infections in High-Risk Cardiac Device Replacements Reported with Use of TYRX Antibacterial Envelope

learn more »

June 24, 2013

Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study in IgA Nephropathy with Blisibimod

learn more »

June 19, 2013

Repurposing a cholesterol drug candidate for cholestatic liver disease

learn more »

May 21, 2013

Liquidia Technologies Announces Extension of Collaboration with PATH to Develop Next Generation Pneumococcal Vaccine

learn more »

May 15, 2013

Art Pappas Elected to NVCA Board of Directors

learn more »

May 15, 2013

Ultragenyx Advances Clinical Development of UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)

learn more »

May 10, 2013

Independent Study Shows Significant Decline in Cardiac Device Infections with TYRX® Antibacterial Envelope

learn more »

May 2, 2013

Nanotechnology firm Liquidia plans new ophthalmology company

learn more »

May 1, 2013

Ultragenyx Appoints Eric Yuen, MD as Chief Medical Officer and Senior Vice President

learn more »

April 15, 2013

TYRX® Announces First EverImplantation of AIGISRx® R Fully Resorbable Antibacterial Envelope

learn more »

April 12, 2013

Chimerix stock pops 34% after IPO at $14 per share

learn more »

April 11, 2013

Chimerix Announces Pricing of Initial Public Offering

learn more »

April 8, 2013

Ultragenyx Initiates Novel Disease Monitoring Program for Hereditary Inclusion Body Myopathy

learn more »

March 12, 2013

Planning IPO, Chimerix says its antiviral makes FDA fast track

learn more »

February 26, 2013

Man with a plan: Emil Kakkis aims to lure big-market drugs toward rare diseases

learn more »

February 20, 2013

Ernest Mario named Chairman of Chimerix

learn more »

January 30, 2013

LipoScience Announces Closing of Initial Public Offering

learn more »

January 10, 2013

Ultragenyx Announces In-Licensing of Clinical-Stage Product Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorders

learn more »

January 9, 2013

LIPOSCIENCE COLLABORATES WITH A LEADING ACADEMIC MEDICAL CENTER TO IDENTIFY RISK FACTORS AIMED AT IMPROVING MANAGEMENT OF ACUTE CORONARY SYNDROME

learn more »

December 20, 2012

Ultragenyx Raises $75 Million in Oversubscribed Crossover Financing

learn more »

November 16, 2012

The Wistar Institute Welcomes Three New Board Members

learn more »

November 12, 2012

Chimerix Appoints Michelle Berrey Chief Medical Officer

learn more »

October 25, 2012

Thrasos Secures $35 Million to Fund THR-184 Phase 2 Clinical Program for Treatment of Acute Kidney Injury

learn more »

October 4, 2012

TYRX(R) Receives Health Canada Approval

learn more »

October 2, 2012

FierceMedicalDevices Names TYRX® as one of its “Fierce 15” Medical Device and Diagnostic Companies of 2012

learn more »

October 2, 2012

CardioDx Honored as One of FierceMedicalDevices’ Fierce 15 Most Promising Private Companies

learn more »

September 27, 2012

IlluminOss Medical Secures $28 Million Series C Financing for Minimally Invasive Bone Fracture Repair

learn more »

September 19, 2012

Pappas-backed CoLucid gets FDA accord

learn more »

September 18, 2012

CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy

learn more »

September 14, 2012

TYRX(R) Receives New Product Innovation Award

learn more »

September 5, 2012

LipoScience Receives FDA Clearance for Vantera Clinical Analyzer

learn more »

August 27, 2012

CardioDx Completes $58 Million Equity Financing

learn more »

August 21, 2012

Over 50% of Hospital CFOs Plan to Adopt New Technology in Response to Medicare Cuts for Cardiac Device Infections

learn more »

August 8, 2012

CardioDx Wins Medicare OK of Molecular Test for Heart Disease

learn more »

August 2, 2012

TYRX® Comments on Medicare Decision to Stop Paying for Infections Following Pacemaker or Defibrillator Implants Release

learn more »

July 24, 2012

Merck snags Chimerix antiviral HIV program in $168.5M deal

learn more »

July 12, 2012

Clinical Data Finds Strong Association Between HDL Particles and Coronary Heart Disease

learn more »

July 9, 2012

Pappas Ventures Names Pat Gage to Scientific Advisory Board

learn more »

July 5, 2012

Ultragenyx Initiates Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy

learn more »

June 29, 2012

Tesaro raises $81M in a rare IPO success story

learn more »

June 25, 2012

MethylGene Announces Encouraging Data from Phase 1 Tumor Study

learn more »

June 20, 2012

Liquidia Announces Product Development Collaboration with GlaxoSmithKline

learn more »

June 6, 2012

Biotech All Stars Buy Castoff Experimental Merck Cancer Drug

learn more »

May 15, 2012

Liquidia Technologies Inc. Studies Show PRINT® Engineered Particles Hold Promise in the Delivery of Respiratory Therapeutics

learn more »

May 15, 2012

Achillion gets FDA Incentives for Hepatitis C Drug

learn more »

May 1, 2012

Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease

learn more »

April 30, 2012

CardioDx Honored as 2012 Gold Edison Award Winner

learn more »

April 26, 2012

LipoScience Receives 2012 Diagnostic Marketing Association Creative Communications First Place Award

learn more »

April 2, 2012

Big Business Appeal of Nanotechnology on Display in Durham

learn more »

March 27, 2012

Athersys gets OK for German solid organ transplant clinical trial

learn more »

March 26, 2012

TESARO promises rapid progress with cancer drugs in $86M IPO

learn more »

March 21, 2012

Stem Cell Therapy Holds Promise for Strokes

learn more »

March 14, 2012

Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 MPS 7

learn more »

March 9, 2012

Ultragenyx Announces the Completion of the Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease

learn more »

March 5, 2012

Milestone Pharmaceuticals Appoints Paul Truex to the Board of Directors

learn more »

February 29, 2012

BrainCells Inc. Announces the Successful Completion of the Single Ascending Dose Study With BCI-838 and the Initiation of the Multiple Ascending Dose Study

learn more »

February 28, 2012

FDA grants orphan drug designation to Ultragenyx UX003 for treatment of MPS 7

learn more »

February 21, 2012

Plexxikon receives European approval for Zelboraf

learn more »

February 21, 2012

Diabetes drug developer Lumena raises $2.5M; compound regulates blood sugar

learn more »

February 16, 2012

First and Only Personalized Treatment for Deadliest Form of Skin Cancer Approved by Health Canada

learn more »

February 6, 2012

Transplant antiviral strong in phase 2; Chimerix plans phase 3 start this year

learn more »

February 1, 2012

A Path Forward for the FDA

learn more »

February 1, 2012

Athersys, Inc. Announces Positive Results of MultiStem(R) Clinical Trial for Hematopoietic Stem Cell Transplant Support and Prevention of Graft-Versus-Host Disease

learn more »

January 27, 2012

Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in Prophylaxis of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients

learn more »

January 23, 2012

Selventa Granted Patent for Discovery of Biomarker Profiles

learn more »

January 19, 2012

Researchers uncover how new melanoma drug accelerates secondary skin cancers

learn more »

January 16, 2012

Venture-Backed Biotech’s 2011 M&A Exits Outpaced Both Investments and Fundraising

learn more »

January 4, 2012

ACH-1625 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C

learn more »

See how Pappas Ventures can advance your innovative idea.

click here »

Learn more about our companies that are making the news.

click here »